Pfizer Tofacitinib’s Fate May Rest On Radiographic Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The marketability and even the approvability of the first-in-class JAK inhibitor for treatment of rheumatoid arthritis may hinge on whether it can be shown to offer patients a structural benefit. FDA briefing documents for the May 9 advisory committee review show issues with those findings.
You may also be interested in...
Oral Dosing May Not Be Enough To Win Speedy Adoption Of Pfizer’s RA Pill Xeljanz
Pfizer’s newly approved oral RA therapy Xeljanz has an oral advantage over established immune modulators, which all are delivered by needle, but safety questions may slow its adoption.
Tofacitinib Delay May Give FDA Time To Look At New Radiographic Data
FDA has extended the review deadline to look over requested data on tofacitinib, but Pfizer also is interested in turning over an interim analysis of the ORAL Start study, which provides radiographic evidence of tofacitinib’s structural benefit in rheumatoid arthritis, a weak point in the NDA.
Tofacitinib Delay May Give FDA Time To Look At New Radiographic Data
FDA has extended the review deadline to look over requested data on tofacitinib, but Pfizer is also interested in turning over an interim analysis of the ORAL Start study, which provides radiographic evidence of tofacitinib’s structural benefit in rheumatoid arthritis, a weak point in the NDA.